Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Diabetes Mellitus Type 2 Pathophysiology

Type 2 Diabetes Symptoms

Type 2 Diabetes Diagnosis

Type 2 Diabetes Screening and Prevention

Type 2 Diabetes Treatment

Living With Type 2 Diabetes

Vitamin D and Type 2 Diabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

What is Insulin Resistance?

Insulin Resistance Pathophysiology

See more featured articles »

Causes of Insulin Resistance

Insulin Resistance Treatment

Insulin Resistance Diagnosis

Insulin Resistance Symptoms

Insulin Resistance and Parkinson's Disease

Does the Keto Diet Increase the Risk of Diabetes?

The Risks of Prediabetes

What is Diabetes?

Fibromyalgia and Diabetes

Diabetes in Men versus Women

Insulin Medication

Latest Type 2 Diabetes News and Research

Online group programs aid weight loss but face hurdles

Online, group-based interventions show promise for weight loss in adults with severe obesity, though barriers like digital literacy and engagement need addressing.

20 Nov 2024

Are diverse diets always healthy?

A study explores the link between diverse, healthy diets and chronic disease risks, finding differing impacts on stroke risk between men and women.

20 Nov 2024

Study reveals slower fat gain in babies exposed to gestational diabetes

A new study led by researchers at The University of Texas at Austin and Harvard Medical School reveals surprising findings about how babies exposed to gestational diabetes mellitus (GDM) grow during their first year of life.

20 Nov 2024

Timing of meals impacts glucose tolerance and health

Although people have always said that having a light and early dinner is better, a study by the Universitat Oberta de Catalunya (UOC) and Columbia University has provided the scientific grounds for this argument.

20 Nov 2024

More than half of all US adults are eligible for semaglutide therapy

Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and cardiovascular disease prevention.

20 Nov 2024

Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options

Metformin and GLP-1 receptor agonists significantly reduce asthma attacks in patients with type 2 diabetes, offering potential new treatments for asthma.

19 Nov 2024

Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

19 Nov 2024

Anti-obesity drugs show promise in improving cardiovascular health beyond weight loss

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, that are being simultaneously presented at the American Heart Association's 2024 Scientific Sessions.

19 Nov 2024

UQ swimming program reverses motor decline in young people with severe cerebral palsy

A competitive swimming program developed by University of Queensland researchers for young people with severe cerebral palsy has reversed motor decline associated with the condition.

19 Nov 2024

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with mixed results from clinical trials.

19 Nov 2024

How alcohol impacts male health

This research explores how alcohol consumption disrupts metabolism, damages the liver, and impairs male reproductive health, emphasizing the complex mechanisms and public health implications.

18 Nov 2024

Proactively screening diabetes patients for heart disease does not improve long-term survival

While coronary heart disease and diabetes are often seen in the same patients, a diagnosis of diabetes does not necessarily mean that patients also have coronary heart disease, according to a new study from researchers at Intermountain Health in Salt Lake City.

18 Nov 2024

Blood pressure control improved with dual medication pills in India

Medication variations that combined two of three different blood pressure-lowering medications into a single pill worked equally well in reducing blood pressure and were safe among adults in India, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Rare variant analysis reveals genetic spectrum of monogenic diabetes genes

This study links rare genetic variants to type 2 diabetes risk, emphasizing their role in monogenic diabetes and potential for precision medicine integration.

18 Nov 2024

Intravenous infusion of exenatide fails to reduce risks of complications in heart surgery patients

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the risk of death, stroke or organ failure.

18 Nov 2024

Intensive blood pressure treatment reduces cardiovascular risk in people with Type 2 diabetes

An intensive treatment approach to lowering high systolic blood pressure in people with Type 2 diabetes led to a reduced risk of heart attack, stroke, heart failure and death due to cardiovascular disease when compared to a standard treatment approach, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Tirzepatide improves heart health and function in obese HFpEF patients

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients

Type 2 diabetes can lead to diabetic kidney disease, but a class of drugs that cause the kidneys to remove glucose through urine has been gaining attention.

18 Nov 2024

Diabetes rates skyrocket globally with millions left untreated

The total number of adults living with either type 1 or type 2 diabetes in the world has surpassed 800 million - over four times the total number in 1990, according to findings from a global analysis published ahead of World Diabetes Day in The Lancet.

18 Nov 2024

Spermidine regulates RIPK1 to combat diabetes and vascular damage

Researchers reveal that spermidine-mediated acetylhypusination of RIPK1 suppresses necroptosis and insulin resistance, offering potential therapeutic strategies for type 2 diabetes.

18 Nov 2024